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&p.1:Abstract Keratin intermediate filaments are formed in
epithelial cells in a cell- and tissue-specific manner, but
much remains unknown regarding the mechanisms
which control the synthesis of these proteins. We exam-
ined the effect of the differentiation modulation agent,
bromodeoxyuridine (BrdU), on two human keratin-nega-
tive (by immunocytochemistry) lung cell lines, DLKP
and H82, and showed immunohistochemically that treat-
ment with 10 µM BrdU over 7 days induced K8 and K18
protein synthesis in both lines. Immunoprecipitation and
Western blot analyses revealed low levels of K8 and K18
proteins in untreated cell homogenates. These levels in-
creased following treatment with BrdU for 7 days. K8
and K18 mRNAs were detected by Northern blot and re-
verse transcriptase polymerase chain reaction analyses in
both lines before BrdU treatment, but no increase in
mRNA levels was observed in either cell line over 21
days of treatment. This suggests, firstly, that keratin syn-
thesis is normally blocked at a posttranscriptional level
in DLKP and H82 cells, and secondly, that BrdU can re-
verse this block. A549 is a human lung cell line which
contains K8 and K18 proteins. Treatment with BrdU in-
creased K8 and K18 protein levels in these cells. No cor-
responding increase in K8 mRNA levels occurred, while
an apparent increase in K18 mRNA levels was detected.
HL-60 is a leukaemic cell line of haematopoietic rather
than epithelial lineage which contains K8 and K18
mRNA transcripts prior to BrdU treatment, but does not
contain keratin proteins. Again, K8 and K18 mRNA lev-
els remained unchanged during BrdU treatment. Howev-
er, neither K8 nor K18 proteins were detected following
treatment, although BrdU is known to alter expression of
other genes in HL-60 cells. BrdU thus appears to act at a
posttranscriptional level and in an epithelial-specific
manner to reverse a block in keratin synthesis in keratin-
negative lung cancer cells and increase synthesis in kera-
tin-positive lung cancer cells. This may represent a regu-
latory step in early lung development or a mechanism
whereby tumour cells downregulate expression of a dif-
ferentiated phenotype. &bdy:
Introduction
Intermediate filaments (IFs) form a family of tissue-spe-
cific cytoskeletal proteins. These include keratins, which
are mainly found in epithelia; vimentin, a mesenchymal
protein; desmin, which is specific for muscle cells; glial
fibrillary acidic protein (GFAP), found in glial cells and
astrocytes; neurofilament proteins, which are expressed
in nerve cells; and lamins, which comprise the nuclear
lamina (reviewed in [36]). Keratin intermediate filaments
are among the most differentiation-specific proteins syn-
thesized in epithelial cells. More than 20 different cellu-
lar keratins (known as cytokeratins to distinguish them
from keratins present in nails and hair) have been identi-
fied [27, 28], each of which appears to have a distinctive
pattern of synthesis in normal epithelia [35]. The keratin
family of proteins is generally subdivided into basic type
II keratins (K1–K8) and acidic type I keratins (K9–K20)
[27], which form heteropolymers consisting of at least
one type I and one type II chain [19]. For example, K8
and K18 are partner molecules which dimerise to form
keratin filaments.
During foetal development, keratins are the first inter-
mediate filament proteins detectable, with the simple
epithelial keratins K8 and K18 appearing first [14]. Gene
sequence analysis indicates that the more specialised
keratins, which are expressed at later stages of develop-
ment and differentiation, probably evolved from K8 and
K18 [4, 37]. An elaborate pattern of keratin proteins is
displayed, first in developing, and then in adult epithelia.
For example, both embryonic and adult epidermal basal
cells initially synthesise K5 and K14 proteins [30]. As
these basal cells differentiate, they down-regulate K5 and
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K14 and begin to express K1 and K10 proteins [36]. In
addition, during wound healing and in diseases of hyper-
proliferation, K6 and K16 can be present in suprabasal
epidermal cells [26, 36]. Thus, epithelial cells possess
specific keratin profiles characteristic of their cell type,
stage of development, disease state and degree of differ-
entiation. It is believed that intermediate filaments organ-
ise cellular internal structure and provide mechanical
support [17], and human genetic mutations which result
in disruption of IF cellular networks give rise to often
debilitating skin-blistering disorders where stress causes
cytolysis [16].
While many epithelial tumours retain a profile of ker-
atin synthesis characteristic of their differentiation state
[6], alterations in keratin synthesis during malignancy
have been observed [42, 46]. Variant small cell lung car-
cinoma (SCLC-V) cells in particular, despite being epi-
thelial in origin, often contain no detectable amounts of
keratin [5] and can instead synthesize neurofilaments or
vimentin. DLKP is a cell line which was established in
our laboratory from a tumour histologically diagnosed as
a poorly differentiated lung carcinoma. DLKP cells have
properties which suggest they could be classified as ei-
ther SLCL-V or non-small-cell lung carcinoma with neu-
roendocrine differentiation (NSCLC-NE) [8, 25], as
these tumour types have a similar profile of protein
markers. DLKP contains neurofilament and vimentin
proteins, but no keratin proteins are detectable at the im-
munocytochemical level (nor are other epithelial markers
such as epithelial membrane antigen, epithelial specific
antigen, EP16 or desmosomal proteins).
BrdU is a thymidine analogue capable of inducing
epitheloid morphology and altering the expression of
neuroendocrine markers in SCLC cell lines [13]. The
ability of BrdU to alter differentiation in neuronal, mus-
cle and haematopoietic lineages is also well established
[12, 40, 48]. BrdU competes with thymidine for incorpo-
ration into DNA, a property which has led to its wide-
spread use in cell proliferation assays [10]. While it ap-
pears that BrdU must be incorporated into DNA in order
to modulate differentiation [18], relatively little is known
regarding the mechanism(s) of action involved. There is
evidence that in some systems altered conformation of
BrdU-containing DNA may affect interactions with spe-
cific transcription factors, leading to either inhibition or
induction of differentiation, depending on the cell type
[24]. In order to investigate the mechanisms resulting in
the absence of keratin (and other epithelial-specific pro-
teins) from DLKP cells and a SCLC-V cell line, H82, we
examined the effects of BrdU on keratin synthesis in
these cells.
Methods
Cell lines
The DLKP cell line was derived from a lymph node metastasis of
a human lung carcinoma which was histologically defined as a
poorly differentiated, squamous cell carcinoma [23]. However,
more recent immunohistochemical analysis carried out in this lab-
oratory indicates that the DLKP cell line expresses many features
typical of SCLC-V or NSCLC-NE [25]. These cells were routinely
cultured in a 1:1 mixture of DMEM:Ham’s F12, which was sup-
plemented with 5% foetal calf serum and 2 mM L-glutamine. All
other cell lines used in this study were obtained from the Ameri-
can Type Culture Collection. H82, a human SCLC-V cell line and
HL-60, a human promyelocytic cell line, both of which grow in
suspension, were cultured in RPMI 1640 medium, supplemented
with 10% foetal calf serum and 2 mM L-glutamine. A549, an ad-
herent human adenocarcinoma cell line, was cultured in
DMEM:Hams F12 (1:1), supplemented with 5% foetal calf serum
and 2 mM L-glutamine. All lines were grown in sealed tissue cul-
ture flasks at 37° C except HL-60, which was maintained in vent-
ed flasks at 37° C in 5% CO2.
BrdU treatment of cells for immunocytochemistry
Stock solutions of 10 mM BrdU (Sigma, Poole, UK) were pre-
pared in sterile phosphate-buffered saline (PBS) and stored at - 20°
C. Cells were seeded at densities of 1×103 cells per well on sterile
multiwell Nunc slides (Life Technologies, Paisley, UK) and incu-
bated for 24 h at 37° C in humidified 5% CO2. Appropriate dilu-
tions of BrdU were made in normal growth medium and added to
the cells at a final concentration of 10 µM. Control wells contained
growth medium without BrdU. Slides were incubated at 37° C in
5% CO2 for up to 21 days, during which time the medium was re-
placed every 2–3 days.
Immunocytochemical analyses
For immunocytochemical analyses, adherent cells growing on
multi-well slides were rinsed three times with PBS and fixed at -
20° C for 5 min in methanol, which had been prechilled to - 20° C.
Cells growing in suspension were harvested by centrifugation,
rinsed three times with PBS, cytocentrifuged onto clean glass
slides, and fixed with methanol as above.
Immunocytochemical staining was performed employing either
the avidin-biotin-peroxidase (AB-HRP) or avidin-biotin-alkaline
phosphatase (AB-AP) technique using DAKO Labs ABC visuali-
sing kits (DAKO, High Wycombe, UK) according to the manufac-
turer’s instructions. Briefly, nonspecific binding was blocked using
dilute rabbit serum. For AB-HRP, endogenous peroxidase activity
was quenched prior to blocking using 3% H2O2. Primary antibod-
ies were then incubated for 2 h at 37° C. Secondary antibodies
were incubated for 30 min at room temperature, and following
30 min of incubation with a streptABComplex/HRP or/AP solu-
tion, either HRP reactivity was visualised using a 3,3-diaminoben-
zidine tetrahydrochloride (DAB) chromogen, which resulted in a
brown-coloured precipitate, or AP reactivity was visualised using
Vector red substrate (Vector Labs, Peterborough, UK), which re-
sulted in a red stain. Cells were counterstained with a 2% methyl
green solution or haematoxylin. Primary antibodies used were as
follows: anti-cytokeratin 8 (Sigma, clone no. M20), anit-cytokera-
tin 10 (DAKO, clone no. DE-K10), anti-cytokeratin 14 (Sigma,
clone no. CKB1), anti-cytokeratin 18 (Sigma, clone no. CY-90)
and anti-CD14 (a monoclonal antibody produced at Edinburgh
University, clone no. UCMH1).
Immunoprecipitation and Western blots
For A549 Western blots, cells were harvested by trypsinization
and washed three times with PBS. Equal cell numbers were lysed
in 2.5× loading buffer, which was 2.5 ml 1.25 M Tris-HCl, pH 6.8;
1.0 g sodium dodecyl sulfate (SDS); 5.8 ml glycerol; 1.4 ml H2O,
and separated on 12% polyacrylamide gels. Proteins were trans-
ferred onto nitrocellulose membranes and blocked for 4 h at room
temperature with 5% semi-skimmed dried milk in TBS/0.5%
Tween 20. Membranes were then probed overnight with keratin
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antibodies, washed and probed with an anti-mouse peroxidase-la-
belled secondary antibody for 1 h and visualised by chemilumi-
nescence using ECL reagents (Amersham, Dublin, Ireland). Im-
munoprecipitations were performed using a biotin labelling kit
(Boehringer Mannheim, Lewes, UK). Briefly, cells were harvested
as above, resuspended in lysis buffer of 50 mM sodium borate,
150 mM NaCl, 0.1 mg/ml phenyl methyl sulfonyl furate (PMSF),
1 µg/ml aprotinin, 1 µg/ml leupeptin, 1% Nonidet P-40, 0.5% so-
dium deoxycholate, sonicated until lysed, as determined micro-
scopically, and incubated on ice for 30 min. Lysates were then
centrifuged at 12,000 g for 10 min. Supernatants were transferred
to clean tubes and biotinylation reactions were carried out accord-
ing to the manufacturer’s instructions. Lysates were precleared by
incubating with 20 µl protein-G beads for 1 h at 4° C, centrifuged
at 12,000 g for 40 s at 4° C. Supernatants were then incubated
with 25 µg keratin antibody overnight at 4° C. Then 30 µl protein-
G beads was added to the lysates and incubated for a further 24 h
at 4° C. Beads were washed according to labelling kit instructions,
pelleted at 12,000 g for 20 s, resuspended in 5× loading buffer (see
above) and run on 12% polyacrylamide gels. Proteins were trans-
ferred to nitrocellulose membranes and probed with a biotin anti-
body (Sigma). Bands were visualised by chemiluminescence. For
the low-intensity signals in DLKP, H82 and HL-60 blots, Super-
signal reagents (Pierce Labs, Dublin, Ireland) were used. The
same keratin antibodies were used in the immunocytochemical,
immunoprecipitation and Western blot studies.
RNA isolation and Northern blot analyses
For RNA isolation and Northern blot analyses, cells were grown
in 175-cm2 tissue culture flasks in medium as above and treated
with 10 µM BrdU. Medium was replaced every 2–3 days. Cells
were harvested at various time points for up to 21 days. Total
RNA from pelleted cells was isolated by extraction with TriRe-
agent (Sigma) according to manufacturer’s instructions. RNA
(20 µg) was separated by electrophoresis on 1% agarose-formal-
dehyde gels and transferred onto Hybond N+ membranes (Amers-
ham). Equal loading of gels was confirmed by ethidium bromide
(EtBr) staining of ribosomal RNA bands on gels. Filters were pre-
hybridised and hybridised at 42° C for 16–18 h in 50% form-
amide, 6×SSC, 5×Denharts solution, 0.5% SDS and 100 µg/ml
salmon sperm DNA. Probes were 32P-labelled with a random
primer labelling kit (Promega). Filters were washed once in
2×SSC (5 min), twice in 0.5×SSC/0.1% SDS (30 min) and twice
in 0.1×SSC/0.1% SDS (30 min) at 65° C and exposed to autora-
diographic film. The K8 probe was obtained from the ATCC and
the K18 probe (pK 189) was kindly supplied by Dr. Robert Osh-
ima, The Burnham Institute, La Jolla, Calif., USA. Both probes
are full-length cDNA probes.
Reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis
Total RNA was isolated as described above. First-strand cDNA
was synthesised from 1 µg RNA using oligo (dT) primers (Prome-
ga, Dublin, Ireland). Then 5 µl cDNA was amplified in a 50 µl
PCR reaction solution of 1×Promega Taq polymerase buffer con-
taining 1.5 mM MgCl2, 0.2 mM dNTPs, 20 µM oligonucleotide
primers and 2.5 U Taq polymerase. The PCR program was as fol-
lows: an initial denaturation step of 94° C for 1.5 min, followed by
30 cycles of 94° C for 1.5 min, 55° C for 1 min and 72° C for
3 min, followed by 72° C for 10 min. RT-PCR products were sepa-
rated on a 3% agarose gel by electrophoresis. Sense and antisense
primers, respectively, used for cDNA amplification were as fol-
lows; K8, AACAACCTTAGGCGGCAGCT (cDNA position +449
to +468) and GCCTGAGGAAGTTGATCTCG (cDNA position
+673 to +692), product size 244 bp &fnn.1:1; K18, CAAGATCATC-
GAGGACCTG (cDNA position +436 to +454) and CTCTCCTC-
AATCTGCTGAGA (cDNA position +860 to +879), product size
444 bp &fnn.2:2; b -actin, TGGACATCCGCAAAGACCTGTAC (cDNA
position +901 to +923) and TCAGGAGGAGCAATGATCTTGA
(cDNA position +1021 to +1042), product size 142 bp &fnn.3:3.
Results
Morphological effects of BrdU
The morphologies of DLKP, H82 and A549 were altered
when grown in the presence of 10 µM BrdU. In the case
of DLKP (Fig. 1A, B) and A549, an approximately 5- to
10-fold increase in cell surface area occurred, with most
cells acquiring a stretched, flattened appearance. H82
cells grow in suspension under normal conditions with a
very small proportion (<5%) of cells spontaneously at-
taching gradually over 5–7 days. Following 5 days of
treatment with BrdU, approximately 80%–90% of H82
cells had attached (Fig. 1C, D). Similar effects on mor-
phology and adherence have been reported following
BrdU treatment of other cell types [13, 39, 45]. At 1 µM
and 5 µM, BrdU had similar, but less pronounced, effects
on DLKP and H82, i.e., fewer cells had altered morphol-
ogies or were keratin positive at the lower BrdU concen-
trations. No effect on the morphology of HL-60 cells
was apparent following treatment, with cells remaining
in suspension before and after 10 µM BrdU exposure.
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1 Primer sequences published [7] &/fn:
2 designed from corresponding rat K18 primers published [15] &/fn:
3 designed at NCTCC, Dublin City University, Ireland &/fn:
Fig. 1A–D Effects of bromodeoxyuridine (BrdU) on morphol-
ogies of DLKP and H82 cells showing untreated DLKP cells (A),
DLKP cells cultured in the presence of 10 µM BrdU for 7 days
(B), arrow indicating at least a 10-fold increase in surface area of
some cells. Untreated H82 cells (C) and H82 cells cultured in the
presence of 10 µM BrdU for 7 days (D), arrows showing attached
and spread cells. (Bar 20 µm) &/fig.c:
Cell densities were reduced by approximately 30%–50%
in all four cell lines following treatment with 10 µM
BrdU for 7 days. This was probably due to both inhibi-
tion of proliferation and some toxicity.
Induction of keratin protein synthesis
Each cell line was examined immunocytochemically for
the presence of keratin filaments before and after expo-
sure to 10 µM BrdU. K8, K10, K14 and K18 were select-
ed for initial studies, as these keratins are likely to be ex-
pressed in lung epithelial cells similar to those in our
study [35]. K8 and K18 were not detected by immunocy-
tochemistry or Western blot analysis in DLKP or H82
cells before treatment with BrdU, but following treat-
ment, K8- and K18-containing filaments were present in
approximately 10% of DLKP and 50% of H82 cells (Fig.
2). Increased numbers of K8- and K18-positive cells and
increased intensity of staining was evident in DLKP cells
treated with BrdU for 21 days (Fig. 2E, F). The keratin
filaments extended from the nuclear lamina out to the
cell membrane (Fig. 3) indicating that K8 and K18 pro-
teins induced by BrdU were functional and capable of
dimerisation and filament assembly. Subsequent immu-
noprecipitation and Western blot studies revealed low
levels of K8 and K18 proteins in DLKP and H82 prior to
treatment and increased levels of both proteins in each
cell line after 7 days of BrdU exposure (Fig. 5). Neither
K10 nor K14 proteins were detected in either cell line
before or after treatment (results not shown).
K8 and K18 filaments were present in A549 cells pri-
or to BrdU treatment (Fig. 4A, B). Increased K8 and
K18 protein synthesis was detected immunocytochemi-
cally following treatment (Fig. 4C–F), and this was con-
firmed by Western blotting (Fig. 5). Unlike DLKP, H82
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Fig. 2A–J Immunocytochemical detection of keratin (K) proteins
in BrdU-treated DLKP and H82 cells. Untreated DLKP cells did
not stain for K8 (A) or K18 (B) on day 7. DLKP cells cultured for
7 days in the presence of 10 µM BrdU expressed K8 (C) and K18
(D) proteins. K8 (E) and K18 (F) staining increased further in
DLKP cells treated for 21 days. Similarly, untreated H82 cells
were negative for K8 (G) and K18 (H) on day 7 while K8 (I) and
K18 (J) proteins were expressed in H82 cells following BrdU
treatment for 7 days. (Bars A–F 20 µm; G–J 10 µm) &/fig.c:
Fig. 3 Immunocytochemical demonstration of K18 filament as-
sembly in BrdU-treated DLKP cells. Filaments were seen to radi-
ate from the nucleus, throughout the cytoplasm, to the cell mem-
brane. (Bar 6 µm). Similar filaments were seen in cells stained
with K8 antibody (not shown) &/fig.c:
and HL-60, immunoprecipitation prior to Western blot-
ting was not required to detect K8 and K18 proteins in
A549 cell lysates as signals were sufficiently strong.
Again, K10 and K14 proteins were absent both before
and after treatment (results not shown). None of the ker-
atin proteins examined here were detected immunohisto-
chemically or by Western blotting or by immunoprecipi-
tation in HL-60 cells before or after exposure to BrdU
(Figs. 4G–J and 5). CD 14 was used as a positive control
in HL-60 immunohistochemistry experiments.
The possibility that keratin synthesis occurred as a re-
sult of toxic stress induced by BrdU, rather than a specif-
ic differentiation effect, was investigated by exposing
each cell line to the chemotherapeutic drug adriamycin.
Exposure to 0.02 µg/ml adriamycin for 7 days resulted in
approximately 75% cell death. However, none of the
BrdU-induced effects such as keratin synthesis, in-
creased cell size or increased adherence occurred in re-
sponse to adriamycin exposure (results not shown).
Keratin mRNA levels following BrdU treatment
To determine if the induction and upregulation of keratin
protein synthesis observed in these lung cell lines reflect-
ed alterations in transcription of their respective genes,
Northern blot analyses were carried out. K8 and K18
mRNA levels were examined before and after BrdU
treatment. K8 mRNA was present in all four cell lines
prior to treatment with BrdU, although, as was also the
case for K18, A549 produced the strongest signals (Fig.
6). K8 mRNA levels did not increase in any cell line over
21 days of BrdU treatment. K18 mRNA was present in
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Fig. 4A–J Immunocytochemical analysis of keratin protein ex-
pression in A549 and HL-60 cells. Untreated A549 cells were posi-
tive for K8 (A) and K18 (B) on day 7. K8 (C) and K 18 (D) ex-
pression appeared upregulated in 10 µM BrdU-treated A549 cells
on day 7. Expression of K8 (E) and K18 (F) remained upregulated
after 21 days of BrdU treatment, although cultures were approach-
ing confluency at this time. Untreated HL-60 cells were negative
for K8 (G) and for K18 (not shown) on day 7. HL-60 cells treated
with BrdU for 7 days were also negative for K8 (H) and K18 (I),
but positive for CD14 (J), a positive control. (Bar 20 µm) &/fig.c:
Fig. 5 Immunoprecipitation and Western blot analyses of K8 and
K18 proteins in each cell line following treatment with 10 µM
BrdU for 7 days. For DLKP, H82 and HL-60, 1×107 cells per im-
munprecipitation reaction were used. H82 cells contained very low
levels of K8 and K18 proteins prior to treatment, resulting in bare-
ly visible signals. Stronger signals, though still relatively weak,
were present after treatment. No K8 and K18 proteins were detect-
ed in HL-60 lysates before or after BrdU treatment. Immunopre-
cipitation was not required to detect A549 K8 or K18 proteins by
Western blot and 2×104 cells were run per lane &/fig.c:
each cell line with the exception of HL-60, where no K18
mRNA was detectable in Northern blots before or after
BrdU treatment. K18 levels remained unchanged in
DLKP and H82 following treatment. However, it is pos-
sible that BrdU induced an increase in A549 K18 mRNA.
RT-PCR was carried out using K18-specific primers
to determine if low levels of mRNA which were unde-
tectable by Northern blot analysis were present in HL-60
cells. K18 mRNA was subsequently detected in HL-60
cells both before and after BrdU treatment (Fig. 7). The
RT-PCR data are not quantitative but specifically demon-
strate the presence of K18 mRNA transcripts. RT-PCR
was also carried out on total RNA from DLKP, H82, and
A549, and K8 and K18 transcripts were again shown to
be present in each cell line prior to and during BrdU
treatment, confirming the Northern blot results (results
not shown).
Discussion
Relatively little is known concerning the mechanisms
which control the complex patterns of keratin protein
synthesis in epithelial cells. While posttranscriptional [3,
9, 22, 32, 38] and, less frequently, translational [38, 44]
and posttranslational [2, 17] regulation of keratin synthe-
sis have been reported, most studies carried out to date
have demonstrated regulation to be at the mRNA level
[3, 34, 36]. In vitro cell culture systems have indicated
that agents as varied as retinoids [20], thyroid hormone
[41], calcium [49], nickel [3] and transformation by
SV40 [29] can alter keratin protein synthesis.
We have investigated the effect of the differentiation
modulation agent, BrdU, on keratin synthesis in keratin-
negative human lung tumour cell lines. Only one other
report of a related study appears in the literature, where
Pampinella et al. [33] observed K8 and K18 protein syn-
thesis in rabbit serosal cells following BrdU treatment,
while untreated cells contained only K18. Messenger
RNA levels were not examined in their study. Such find-
ings have led to speculation that genes encoding so-
called ‘epithelial-specific’ proteins such as keratins are
not as strictly regulated as was once believed [21]. Sev-
eral reports describe the detection of keratin mRNA tran-
scripts in cells which do not contain the corresponding
keratin proteins. K8 mRNA is present in rat liver epithe-
lial cell lines which do not express K8 protein [2], and
K8 and K18 mRNAs have been detected in normal bone
marrow, normal lymph node and normal peripheral
blood cells, cultured endothelial cells and cultured skin
fibroblasts [7, 43]. Similarly, each of the three keratin-
negative cell lines used in our study was found to contain
keratin mRNA transcripts prior to treatment with BrdU,
demonstrating that controls other than those at the gene-
transcriptional level are involved in keratin synthesis in
these cells.
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Fig. 6 Northern blot analysis of K8 and K18 mRNA in each cell
line. Ethidium bromide staining of 28S rRNA is indicated to dem-
onstrate equal loading. A K18 signal was not detectable in HL-60
cells. A549 blots were exposed at - 70° C for 16 h and all others
for 10 days &/fig.c:
Fig. 7 Reverse transcriptase polymerase chain reaction analysis of
K18 mRNA in HL-60 cells treated with 10 µM BrdU for 21 days.
b -Actin was used as an internal control. Lane M contains molecu-
lar-weight markers
Tyner and Fuchs [44] have also demonstrated the
presence of K6 and K14 mRNA in skin in the absence of
corresponding proteins. The authors propose that an un-
identified physiological block in translation prevents K6
protein synthesis until required during episodes of hyper-
proliferation, and that deregulation of this block could be
associated with some disease states. Understanding the
mechanism of such differentiation blocks has led to de-
velopments in differentiation therapy. Most notably, in
the case of acute promyelocytic leukaemia (APL), all-
trans retinoic acid successfully reverses the arrest in
maturation of blood cells which leads to APL [31]. Iden-
tification of other blocks in cancer cell differentiation
should reveal possibilities for similar strategies.
Most epithelial tumours synthesise keratin proteins,
although it is not clear if the structure and function of
these keratin filaments is identical to that of normal cells.
An exception is SCLC-V, where keratin proteins are of-
ten absent. Alterations in cell adhesion molecules have
also been reported in these cells [8]. In general, in vivo,
these poorly-differentiated tumours exhibit increased in-
vasiveness and have a poorer prognosis compared to
well-differentiated tumours [1]. The loss of function or
alteration of epithelial features such as keratins and pro-
teins involved in cell-cell and cell-matrix contacts ap-
pears to facilitate cell migration and metastasis. Howev-
er, the molecular mechanisms controlling these blocks in
differentiation are unclear. We have demonstrated that a
block in K8 and K18 protein synthesis and filament for-
mation occurs at a posttranscriptional level in DLKP and
H82 cells and that BrdU exposure results in the removal
of this block. Whether this is by positive or negative reg-
ulation is unclear at the moment. Although K8 and K18
proteins were not immunocytochemically detectable in
untreated DLKP or H82 cells, the same keratin antibod-
ies could detect low levels of these proteins in the more-
sensitive immunoprecipitation and Western-blot studies.
This may be due to a basal level of translation activity,
unstable translation products or soluble forms of keratin
molecules which cannot dimerise and form filaments. In
three of the four cell lines examined here, BrdU did not
alter keratin mRNA levels, suggesting its effect was di-
rectly or indirectly on protein translation or stabilisation
of translation products already prsent, or both. The in-
crease in keratin protein levels observed in keratin-posi-
tive A549 cells could also reflect an increase in either
translation or stability of translation products, although
K18 mRNA levels appeared elevated following BrdU
treatment, indicating control at the transcriptional and/or
posttranscriptional level may also occur in this cell line.
Keratin protein synthesis in response to BrdU was
limited to a proportion of DLKP and H82 cells. Double-
labelling in situ hybridisation and immunocytochemical
studies will be required to determine whether keratin
mRNA transcripts are present only in those cells which
proceed to synthesise keratin protein, or whether keratin
mRNA is universally present but translated only in a sub-
population of permissive cells. Heterogeneity in keratin
protein synthesis may reflect the presence of different
subpopulations within the tumour cell lines. DLKP con-
tains at least three such populations [25], but each has
been found to express K8 and K18 in response to BrdU
treatment (results not shown). Heterogeneous responses
have been previously reported using calcium as a differ-
entiating agent for normal mouse epidermal cells, where
keratin synthesis was shown only in a minority
(10%–50%) of cells [34, 49]. Further studies examining
a range of culture conditions including various differenti-
ating agents may reveal circumstances under which kera-
tin protein synthesis is inducible in a higher proportion
of cells.
It has been proposed that BrdU selectively modulates
the expression of a class of regulatory genes which are
important in the differentiation processes of various cell
lineages [40]. The effects of BrdU on HL-60 haemato-
poietic cell differentiation are well documented [47, 48].
However, we found that BrdU does not induce keratin
protein synthesis in these cells as it does in epithelial
cells, despite the presence of the corresponding keratin
mRNA. This may indicate that an alternative mechanism
which BrdU does not affect prevents keratin protein syn-
thesis in haematopoietic cells, in contrast to lung epithe-
lial cells. Alterations in cellular morphology were also
apparent in DLKP, H82 and A549 cells treated with
BrdU. H82 cells were induced to adhere and spread, in-
dicating that changes in the expression of cell adhesion
molecules may have occurred in addition to alterations in
cytoskeletal proteins. An increase in cell surface area
was also evident in DLKP and A549 cells. No such mor-
phological effects were apparent in BrdU-treated HL-60
cells. This indicates that BrdU may be affecting these
cell lines in a lineage-specific manner, altering the syn-
thesis of epithelial cytoskeletal proteins and adhesion
molecules in DLKP, H82 and A549, but affecting a dif-
ferent set of haematopoietic-related proteins in HL-60,
as has previously been determined [47, 48]. We are cur-
rently investigating possible alterations in the synthesis
of adhesion molecules and other epithelial-specific pro-
teins in BrdU-treated cells in order to more fully char-
acterise the differentiation pathways involved.
In conclusion, there appears to be a posttranscription-
al block on K8 and K18 synthesis in DLKP and H82
cells which can be reversed by exposure to BrdU. In ad-
dition, BrdU-induced keratin protein synthesis seems to
be epithelial cell-specific. While the extent to which this
process corresponds to epithelial differentiation in vivo
remains to be determined, it should nonetheless prove to
be a useful system for examining mechanisms which
lead to blocks in epithelial differentiation and subsequent
tumour formation. It is also possible that this regulatory
step is involved in normal physiological maturation of
primitive or stem cell-stage lung epithelial cells [11].
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